Posts By: pharmanewsdaily

Tagrisso FLAURA trial results : AstraZeneca NSCLC drug significantly improves OS

Tagrisso FLAURA trial results : Pharma giant AstraZeneca said that the phase 3 FLAURA trial evaluating Tagrisso (osimertinib) in previously untreated patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) has yielded positive overall survival (OS) results. The randomized, double-blinded, multicenter late-stage trial featured NSCLC patients whose tumors have epidermal growth factor receptor (EGFR) […]

The post Tagrisso FLAURA trial results : AstraZeneca NSCLC drug significantly improves OS appeared first on PharmaNewsDaily.com.

Boston Scientific to be distributor of Endologix products in China

US medical devices company Endologix, which develops minimally invasive treatments for aortic disorders, signed an agreement with medical devices manufacturer Boston Scientific under which the latter becomes the exclusive distributor for its products in China. The long-term agreement covers distribution rights to Endologix’s EndoVascular Aneurysm Repair (EVAR) and Endovascular Aneurysm Sealing (EVAS) products, and also […]

The post Boston Scientific to be distributor of Endologix products in China appeared first on PharmaNewsDaily.com.

Gilead Sciences announces Biktarvy China approval for HIV-1

Biktarvy China approval : US biopharma company Gilead Sciences said that the China National Medical Products Administration (NMPA) has approved Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg, BIC/FTC/TAF) for the treatment of HIV-1 infection. The once-daily single tablet regimen (STR) Biktarvy is a combination of the unboosted integrase strand transfer inhibitor (INSTI) bictegravir and the dual […]

The post Gilead Sciences announces Biktarvy China approval for HIV-1 appeared first on PharmaNewsDaily.com.

ORIC Pharmaceuticals raises $55m to advance cancer resistance drugs

US oncology company ORIC Pharmaceuticals has raised $55 million through a Series D financing round to advance its pipeline of cancer resistance drugs, as per the latest pharma industry news. The financing brings the total capital raised by the San Fransisco-based ORIC Pharmaceuticals to more than $175 million. Leading the Series D financing round of the […]

The post ORIC Pharmaceuticals raises $55m to advance cancer resistance drugs appeared first on PharmaNewsDaily.com.

Dynacure’s centronuclear myopathies drug DYN101 gets FDA orphan drug designation

French pharma company Dynacure has secured orphan drug designation for its investigational antisense drug DYN101 from the US Food and Drug Administration (FDA) for the treatment of Centronuclear Myopathies (CNM). DYN101, which is designed to modulate the expression of dynamin 2 (DNM2), will undergo its first human clinical trial in the form of the Unite-CNM […]

The post Dynacure’s centronuclear myopathies drug DYN101 gets FDA orphan drug designation appeared first on PharmaNewsDaily.com.

Windgap Medical, ALK-Abello forge partnership for epinephrine autoinjector

Windgap Medical has forged a partnership with ALK-Abello to commercialize the former’s epinephrine autoinjector (EAI) for the treatment of anaphylactic shock. As per the agreement, ALK-Abello will have exclusive, worldwide sales and distribution rights for the Windgap epinephrine autoinjector. For this, ALK-Abello will be making up-front, technical, and sales milestone payments plus tiered royalties on […]

The post Windgap Medical, ALK-Abello forge partnership for epinephrine autoinjector appeared first on PharmaNewsDaily.com.

Permira Funds to acquire US CDMO Cambrex for $2.4bn

Permira acquisition of Cambrex : Global investment firm Permira Funds, through one of its affiliates, has agreed to acquire US contract development and manufacturing organization (US CDMO) Cambrex for about $2.4 billion, including the assumption of its net debt. Based in New Jersey, Cambrex is a small molecule company that offers drug substance, drug product, and […]

The post Permira Funds to acquire US CDMO Cambrex for $2.4bn appeared first on PharmaNewsDaily.com.

Stokes’ STK-001 secures FDA orphan drug designation for Dravet Syndrome

US biotech company Stoke Therapeutics has secured orphan drug designation for its lead product candidate – STK-001 from the US Food and Drug Administration (FDA) for the treatment for Dravet syndrome. Considered to be a severe and progressive genetic epilepsy, Dravet syndrome is characterized by frequent, prolonged and refractory seizures that start within the first […]

The post Stokes’ STK-001 secures FDA orphan drug designation for Dravet Syndrome appeared first on PharmaNewsDaily.com.

Astellas doses first patient in phase 3 VMS trial of fezolinetant

Japanese pharma company Astellas Pharma has dosed the first patient in the SKYLIGHT 1 phase 3 trial for fezolinetant, an investigational oral, non-hormonal compound for the treatment of moderate-to-severe vasomotor symptoms (VMS) associated with menopause. Vasomotor symptoms are hot flashes and night sweats which occur in nearly 57% on women, aged 40-64 years as per […]

The post Astellas doses first patient in phase 3 VMS trial of fezolinetant appeared first on PharmaNewsDaily.com.

Foamix files NDA seeking FMX103 FDA approval for rosacea

Israeli pharma company Foamix Pharmaceuticals has filed a new drug application (NDA) for FMX103 to the US Food and Drug Administration (FDA) seeking FMX103 FDA approval for moderate-to-severe papulopustular rosacea in patients, aged 18 years and over. Considered to be a common skin condition, rosacea results in redness and visible blood vessels in the face. […]

The post Foamix files NDA seeking FMX103 FDA approval for rosacea appeared first on PharmaNewsDaily.com.

Scroll To Top